UEC enters the week as the worst-performing name in the uranium complex — down 23% in five sessions to $11.91 — yet short sellers show no sign of retreating.
Short interest has become the central tension here. At 12.3% of the free float and barely changed from a month ago, shorts have been building steadily since late March when the reading was closer to 10.4%. The position has grown by roughly 5.9% over the past month — a measured accumulation, not a frantic pile-on — which makes the price collapse all the more notable: bears were already in place before the move and have not rushed to cover. Days to cover clocks in at 6.2 days per the latest FINRA settlement data, a reading that ranks in the third percentile of the universe. That tells you unwinding this short book is not a quick exercise.
The borrow market offers little squeeze pressure, however. Availability is running at roughly 197% of short interest — nearly two shares available to borrow for every one currently borrowed — and cost to borrow is just 0.49%, barely changed on the week. That compares to a 52-week availability low of 111%, which itself was never particularly tight. In other words, shares are plentiful for anyone wanting to add to the short. Options traders are equally unmoved: the put/call ratio is 0.40, a full 1.3 standard deviations below its 20-day average — call volume is dominating even as the stock craters. That divergence is worth watching. Either options traders are buying calls speculatively into the dip, or the put side has simply been depleted. The 52-week PCR range runs from 0.15 to 0.79, so the current reading sits in the lower half — tilted toward calls, not panic.
The Street remains firmly bullish, at odds with the price action. HC Wainwright reiterated its Buy rating and $26.75 target this week — the most recent analyst action, filed just today. TD Securities trimmed its target to $21 from $22 back in March while keeping its Buy. The mean analyst target from the available data is $19.17, implying roughly 61% upside from current levels — a gap that reflects either a significant disconnect between analyst expectations and the market, or lags in the data given the uranium sector's volatility. Goldman Sachs carried a Buy with a $17 target as of last September, though that figure is now several months old and may not reflect current conditions. The EPS surprise factor score ranks in the 93rd percentile, and forward EPS momentum over 12 months sits at the 83rd percentile — the fundamental story, by those measures, has not deteriorated. The ORTEX short score is 66.2, a level it has held without much change for the past two weeks, suggesting no fresh acceleration in short conviction.
Peers confirm this is a sector-wide rout, not a UEC-specific one. EFR dropped 12.3% on the day and 22.6% on the week — almost identical to UEC's slide. CCO, the sector bellwether, fell a more contained 3.9% on the day and 11.1% on the week. That relative resilience from Cameco is notable: the larger, more liquid names are holding better, while junior and mid-tier uranium plays — NXE, DML, URC — are all down 14–18% over five sessions. The sell-off looks like a rotation out of higher-beta uranium exposure rather than a fundamental reassessment of any single company.
The bull case rests on near-term project catalysts: Burke Hollow construction completion, Roughrider development, and $486M in cash with physical uranium inventories near $144M. The bear case centres on the decision to skip spot uranium sales in Q1 2026 and production underperformance at Irigaray during upgrades — signals that operational execution may lag the project pipeline narrative. With no confirmed next earnings date in the snapshot, the near-term question is whether the uranium spot price stabilises enough to give management cover to resume spot sales — and whether that, in turn, shifts the analyst-versus-market gap.
See the live data behind this article on ORTEX.
Open UEC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
